FDA Grants Priority Review for Amgen's sNDA for Expanded Labeling of Kyprolis® in Relapsed Multiple Myeloma

The US Food and Drug Administration (FDA) has agreed for priority review of Amgen's supplemental new drug application (sNDA) for expanded labeling of Kyprolis (carfilzomib) in relapsed multiple myeloma.
Source: International Myeloma Foundation - Category: Hematology Source Type: news